All Day Stocks

[Robertscott]

$ONCX
Prolanta™ has already been given Orphan Drug status by the FDA. Orphan Drugs enjoy a number of different privileges because they treat diseases that may not have the same public support as other conditions. By being granted this consideration, Oncolix may save up to $2 million in filing fees. It also makes Oncolix eligible for tax credits and gives them an exclusive hold on the market. This status not only gives them more money to put toward research and development, it also means there’s more money to put toward investment. The communication from the top down has been honest and transparent about every milestone and achievement, making investors eager to see what comes next. Redman is confident that he can build company infrastructure to meet all OTC-QB requirements sooner rather than later. https://smallcapvoice.com/blog/oncolix-inc-oncx-continues-to-impress-by-reaching-important-milestones/